tafamidis   Click here for help

GtoPdb Ligand ID: 8378

Synonyms: FX-1006 | Vyndamax® | Vyndaqel®
Approved drug PDB Ligand
tafamidis is an approved drug (EMA and UK (2011), FDA (2019))
Compound class: Synthetic organic
Comment: Tafamidis binds potently and selectively to transthyretin (TTR), stabilising protein tetramers, thereby inhibiting the formation of amyloid fibrils [2]. The trade name for this drug is Vyndaqel which contains tafamidis meglumine (PubChem CID 24970412). The Vyndamax brand contains tafamidis parent molecule.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 63.33
Molecular weight 306.98
XLogP 4.02
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Clc1cc(Cl)cc(c1)c1nc2c(o1)cc(cc2)C(=O)O
Isomeric SMILES Clc1cc(Cl)cc(c1)c1nc2c(o1)cc(cc2)C(=O)O
InChI InChI=1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H,(H,18,19)
InChI Key TXEIIPDJKFWEEC-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Tafamidis is approved to treat transthyretin (TTR)-mediated amyloidosis (aka familial amyloid polyneuropathy or FAP), a rare hereditary disease caused by amyloid build up in tissues around the body including around the nerves. Its use can reduce cardiovascular mortality and cardiovascular-related hospitalisations in patients with cardiomyopathy resulting from TTR-mediated amyloidosis [4,6]. The drug was granted orphan designation in the EU (2012) for the treatment of senile systemic amyloidosis (SSA), another TTR amyloid disease [7].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Tafamidis stabilises TTR tetramer formation, preventing the dissociation which underlies the mis-folding and aggregation of TTR into amyloid fibrils. The deposition of these fibrils eventually causes degradation of the autonomic nervous system [1].
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)